Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2176157 | 0.83 | GGPS1 (0.34) | — | |
| Bromide SCHEMBL2179553 | 0.82 | LMNA (0.38) | ATML3MBTL1 | |
| SCHEMBL5293853 | 0.79 | TP53 (0.47) | TP53ATMTDP1L3MBTL1 | |
| Bromide SCHEMBL2745244 | 0.73 | CHRNA7 (0.32) | — | |
| SCHEMBL5300656 | 0.73 | TP53 (0.46) | TP53TSHRMAPK1ATMTDP1 | |
| Bromide SCHEMBL28936792 | 0.73 | TP53 (0.41) | TP53L3MBTL1 | |
| Bromide SCHEMBL2178682 | 0.70 | HTT (0.37) | — | |
| SCHEMBL5301505 | 0.70 | TP53 (0.35) | TP53 | |
| SCHEMBL123117 | 0.70 | KMT2A (0.41) | TSHRATMTDP1L3MBTL1 | |
| Bromide SCHEMBL2745044 | 0.69 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071982-B2 | Method of treating neuropathic pain | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF UTAH (US) | 2016-11-24 | — | — | US | claimed |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-09-29 | — | — | US | claimed |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-09 | — | — | US | claimed |
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | claimed |
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-07-07 | — | — | US | claimed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | claimed |
| US-10071982-B2 | Method of treating neuropathic pain | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF UTAH (US) | 2016-11-24 | — | — | US | disclosed |
| US-9499518-B2 | Bis-quaternary ammonium salts as pain modulating agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-09 | — | — | US | disclosed |
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | TP53 2814/4885TSHR 4661/4885MAPK1 2530/4885 |
| US-10071982-B2 | Method of treating neuropathic pain | INA, GAP43, ACHE | TP53 4689/4885TSHR 4702/4885MAPK1 4209/4885 |
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | TP53 4689/4885TSHR 4702/4885MAPK1 4209/4885 |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | TP53 2814/4885TSHR 4661/4885MAPK1 2530/4885 |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | TP53 4052/4885TSHR 749/4885MAPK1 2717/4885 |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | TP53 4689/4885TSHR 4702/4885MAPK1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.